Index S&P 500
P/E -
EPS (ttm) -8.06
Insider Own 11.70%
Shs Outstand 390.58M
Perf Week -12.92%
Market Cap 9.24B
Forward P/E -
EPS next Y -7.17
Insider Trans -0.00%
Shs Float 344.88M
Perf Month -14.09%
Enterprise Value 5.42B
PEG -
EPS next Q -2.73
Inst Own 78.55%
Short Float 18.86%
Perf Quarter -7.15%
Income -3.12B
P/S 4.14
EPS this Y 6.42%
Inst Trans 1.10%
Short Ratio 5.83
Perf Half Y -2.47%
Sales 2.23B
P/B 0.98
EPS next Y 17.43%
ROA -22.31%
Short Interest 65.04M
Perf YTD -43.12%
Book/sh 24.16
P/C 2.05
EPS next 5Y 20.37%
ROE -29.32%
52W High 56.69 -58.29%
Perf Year -55.62%
Cash/sh 11.53
P/FCF -
EPS past 3/5Y - -42.94%
ROIC -31.11%
52W Low 23.15 2.16%
Perf 3Y -84.09%
Dividend Est. -
EV/EBITDA -
Sales past 3/5Y -43.99% 121.86%
Gross Margin 48.25%
Volatility 5.56% 5.63%
Perf 5Y -64.76%
Dividend TTM -
EV/Sales 2.43
EPS Y/Y TTM 51.07%
Oper. Margin -155.15%
ATR (14) 1.53
Perf 10Y -
Dividend Ex-Date -
Quick Ratio 3.73
Sales Y/Y TTM -56.00%
Profit Margin -139.61%
RSI (14) 40.85
Recom 2.93
Dividend Gr. 3/5Y - -
Current Ratio 3.93
EPS Q/Q -1673.01%
SMA20 -9.15%
Beta 1.13
Target Price 39.32
Payout -
Debt/Eq 0.07
Sales Q/Q -45.44%
SMA50 -8.29%
Rel Volume 0.94
Prev Close 24.33
Employees 5800
LT Debt/Eq 0.07
Earnings Nov 06 BMO
SMA200 -17.61%
Avg Volume 11.15M
Price 23.65
IPO Dec 07, 2018
Option/Short Yes / Yes
EPS/Sales Surpr. 72.79% 10.33%
Trades
Volume 4,396,114
Change -2.79%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-13-25 Initiated
Citigroup
Neutral
$40
Feb-18-25 Downgrade
Barclays
Overweight → Equal Weight
$111 → $45
Jan-29-25 Downgrade
Goldman
Buy → Neutral
$99 → $51
Dec-18-24 Downgrade
Argus
Buy → Hold
Dec-10-24 Resumed
BofA Securities
Underperform
$41
Nov-19-24 Initiated
Berenberg
Hold
$42
Nov-18-24 Upgrade
HSBC Securities
Hold → Buy
$58
Nov-15-24 Initiated
Wolfe Research
Underperform
$40
Oct-17-24 Initiated
Bernstein
Mkt Perform
$55
Sep-13-24 Downgrade
Oppenheimer
Outperform → Perform
Sep-13-24 Downgrade
JP Morgan
Neutral → Underweight
$88 → $70
Sep-13-24 Downgrade
Jefferies
Buy → Hold
$120 → $65
Aug-28-24 Upgrade
HSBC Securities
Reduce → Hold
$82
Aug-07-24 Upgrade
Deutsche Bank
Sell → Hold
$85 → $80
Aug-05-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$125 → $90
Feb-26-24 Downgrade
HSBC Securities
Hold → Reduce
$75 → $86
Jan-02-24 Upgrade
Oppenheimer
Perform → Outperform
$142
Nov-29-23 Initiated
Canaccord Genuity
Hold
$82
Nov-03-23 Upgrade
HSBC Securities
Reduce → Hold
$89 → $69
Nov-02-23 Downgrade
Deutsche Bank
Hold → Sell
$125 → $60
Show Previous Ratings
Today 08:16AM
12:31AM
Nov-06-25 10:30PM
04:40PM
04:09PM
(Investor's Business Daily)
04:03PM
Loading…
04:03PM
03:29PM
02:16PM
02:15PM
02:11PM
11:58AM
11:16AM
11:14AM
10:36AM
10:10AM
09:47AM
Loading…
09:47AM
09:37AM
09:37AM
09:37AM
09:33AM
08:26AM
(Investor's Business Daily)
08:15AM
08:09AM
08:08AM
07:39AM
07:29AM
07:13AM
(Associated Press Finance)
07:09AM
(The Wall Street Journal)
07:00AM
05:32AM
04:25AM
Loading…
04:25AM
Nov-05-25 06:48PM
06:48PM
06:48PM
06:48PM
06:48PM
06:48PM
04:15PM
Nov-04-25 10:21PM
09:45AM
(Associated Press Finance)
08:36AM
Nov-03-25 07:18PM
(Morningstar Research) -8.28%
01:20PM
05:00AM
Oct-31-25 04:25PM
09:00AM
04:56AM
Oct-30-25 07:19PM
(Morningstar Research) +13.93%
04:39PM
01:22PM
10:00AM
Oct-29-25 06:47PM
08:00AM
(Investor's Business Daily)
Oct-24-25 05:45PM
Oct-23-25 04:13PM
(Investor's Business Daily)
02:42PM
02:24PM
10:23AM
07:27AM
07:00AM
Oct-22-25 05:50PM
04:23PM
04:05PM
01:10PM
11:12AM
09:53AM
Oct-21-25 03:34PM
05:05AM
Oct-20-25 03:14PM
02:05PM
(Investor's Business Daily)
Oct-19-25 08:00AM
Oct-17-25 09:59AM
Oct-16-25 07:00AM
Oct-15-25 04:08PM
Oct-14-25 05:50PM
05:27PM
01:33PM
Oct-13-25 12:21PM
Oct-10-25 08:50AM
05:07AM
Oct-08-25 05:50PM
Oct-07-25 06:14AM
(Pharmaceutical Technology)
Oct-06-25 08:50AM
Oct-03-25 11:48AM
Oct-02-25 05:50PM
10:32AM
09:30AM
01:35AM
Oct-01-25 04:20PM
02:48PM
02:08PM
Sep-30-25 07:30AM
Sep-25-25 05:50PM
06:55AM
(Pharmaceutical Technology)
05:34AM
Sep-24-25 07:31PM
07:01PM
05:26PM
Sep-23-25 09:01PM
10:16AM
(The Wall Street Journal)
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hussain Abbas Director Jun 11 '25 Sale 28.00 312 8,736 580 Jun 12 04:22 PM Hussain Abbas Director Jun 11 '25 Proposed Sale 28.00 312 8,736 Jun 11 10:06 AM Bancel Stephane Chief Executive Officer Mar 03 '25 Buy 31.22 160,314 5,004,318 9,210,686 Mar 04 04:27 PM SAGAN PAUL Director Mar 03 '25 Buy 31.76 31,620 1,004,251 312,027 Mar 04 04:24 PM Klinger Shannon Thyme Chief Legal Officer Dec 09 '24 Sale 44.68 529 23,637 20,446 Dec 10 04:08 PM Klinger Shannon Thyme Officer Dec 09 '24 Proposed Sale 44.68 529 23,637 Dec 09 03:18 PM Klinger Shannon Thyme Chief Legal Officer Dec 03 '24 Sale 43.30 112 4,849 19,837 Dec 04 05:11 PM Hoge Stephen President Dec 03 '24 Sale 43.30 314 13,595 1,443,904 Dec 04 05:08 PM Klinger Shannon Thyme Officer Dec 03 '24 Proposed Sale 43.30 112 4,849 Dec 03 04:11 PM Hoge Stephen Officer Dec 03 '24 Proposed Sale 43.30 314 13,595 Dec 03 03:23 PM Mock James M Chief Financial Officer Nov 29 '24 Sale 42.79 1,420 60,761 11,066 Dec 02 04:26 PM Klinger Shannon Thyme Chief Legal Officer Nov 29 '24 Sale 42.79 1,418 60,675 19,717 Dec 02 04:19 PM Hoge Stephen President Nov 29 '24 Sale 42.79 291 12,452 1,443,567 Dec 02 04:15 PM Hoge Stephen Officer Nov 29 '24 Proposed Sale 42.79 291 12,452 Nov 29 03:54 PM Klinger Shannon Thyme Officer Nov 29 '24 Proposed Sale 42.79 1,418 60,675 Nov 29 03:49 PM Mock James M Officer Nov 29 '24 Proposed Sale 42.79 1,420 60,761 Nov 29 03:35 PM Hoge Stephen President Nov 11 '24 Sale 46.10 277 12,771 1,443,248 Nov 12 04:14 PM Hoge Stephen Officer Nov 11 '24 Proposed Sale 46.10 277 12,771 Nov 12 09:27 AM